What is the 13F Pro Quality Score for BIIB?

13F Pro ranks BIOGEN INC. (BIIB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BIIB's current score at https://13fpro.ai/research/BIIB (free sign-up required for the full ranking).

Which hedge funds own the most BIIB stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BIIB include BlackRock,, PRIMECAP MANAGEMENT CO/CA/, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BIIB as soon as new 13F filings post.

Where does 13F Pro source BIIB data?

All BIOGEN INC. fundamentals and ownership data come directly from SEC EDGAR. BIOGEN INC. files with the SEC under CIK 875045. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BIIB in?

BIOGEN INC. (BIIB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BIIB research updated on 13F Pro?

BIIB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BIOGEN INC.(BIIB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 875045 BIIB stock profile & AI dashboard →

13F Pro Quality Score

65.6/100

Rank #567 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

38.7/100

Profitability

82.9/100

Balance Sheet

73.1/100

Earnings Quality

58.9/100

Free Cash Flow

79.7/100

Institutional Flow

13.0/100

Revenue Scale

86.8/100

Dilution Risk

34.1/100

BIIB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BIOGEN INC. (BIIB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BIIB at 65.6/100 on a 32-signal composite quality model, placing it at rank #567 of 2,879 stocks — the top 25% of the AI-ranked universe. BIIB scores in the top quartile across revenue scale (86.8), profitability (82.9), free cash flow (79.7). Areas of concern include institutional flow (13.0) and revenue growth (38.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 34.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), BIOGEN INC. reports quarterly revenue of $2.5B, net income of $319.5M, an operating margin of 15.2%. Top institutional holders of BIIB by reported 13-F value include BlackRock,, PRIMECAP MANAGEMENT CO/CA/, FMR, based on the most recent SEC filings. BIIB trades on the Nasdaq exchange and files with the SEC under CIK 875045. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIIB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOGEN INC. directly from SEC EDGAR. BIOGEN INC.'s 13F Pro composite quality score has ranged between 8 and 75 since 2021, currently 65.6 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about BIOGEN INC.

Quirks, history, and lore behind BIIB — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · large-cap · listed on Nasdaq · headquartered in Cambridge, Massachusetts.
2
The Numbers
Annual revenue in the range of $9–10 billion, yet sales have been under pressure for years as its flagship drugs face generic competition and pipeline bets run expensive.
3
The History
Founded in 1978 by a group that included a Nobel laureate, it was one of the earliest biotech companies ever created — practically a founding myth of the entire industry.
4
The Secret
Its core franchise is built around treating multiple sclerosis, and it has spent decades as the undisputed leader in a disease most pharma giants once ignored.
5
The Lore
It sparked one of biotech's wildest stock rollercoasters when the FDA granted accelerated approval to its controversial Alzheimer's drug in 2021 — dividing scientists and investors alike.
6
The Giveaway
The maker of Tecfidera and Tysabri for MS, and the company whose Alzheimer's bet on aducanumab made headlines around the world — for better and worse.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$2.5B

Net Income

Q1 2026

$319.5M

Free Cash Flow

Q1 2026

$594.3M

Operating Margin

Q1 2026

15.2%

ROIC

Q1 2026

1.5%

D/E Ratio

Q1 2026

0.34

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+2.2% YoY

$9.89BFY 2025

FY22 $10.17BFY23 $9.84BFY24 $9.68BFY25 $9.89B

Net Income

-20.8% YoY

$1.29BFY 2025

FY22 $3.05BFY23 $1.16BFY24 $1.63BFY25 $1.29B

Operating Income

—FY 2025

FY22 —FY23 —FY24 —FY25 —

EPS (Diluted)

-21.4% YoY

$8.79FY 2025

FY22 $20.87FY23 $7.97FY24 $11.18FY25 $8.79

Total Assets

+5.0% YoY

$29.44BFY 2025

FY22 $24.55BFY23 $26.84BFY24 $28.05BFY25 $29.44B

Total Debt

-0.1% YoY

$6.29BFY 2025

FY22 $6.28BFY23 $7.09BFY24 $6.30BFY25 $6.29B

Op. Cash Flow

-23.3% YoY

$2.20BFY 2025

FY22 $1.38BFY23 $1.55BFY24 $2.88BFY25 $2.20B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$9.89B +2.2%	$9.68B -1.6%	$9.84B -3.3%	$10.17B -7.4%	$10.98B -18.3%	$13.44B
Net Income	$1.29B -20.8%	$1.63B +40.6%	$1.16B -61.9%	$3.05B +95.8%	$1.56B -61.1%	$4.00B
Operating Income	—	—	—	—	$2.84B -37.6%	$4.55B
EPS (Diluted)	$8.79 -21.4%	$11.18 +40.3%	$7.97 -61.8%	$20.87 +100.7%	$10.40 -58.1%	$24.80
Total Assets	$29.44B +5.0%	$28.05B +4.5%	$26.84B +9.3%	$24.55B +2.8%	$23.88B -3.0%	$24.62B
Total Debt	$6.29B -0.1%	$6.30B -11.2%	$7.09B +12.9%	$6.28B -13.6%	$7.27B -2.1%	$7.43B
Operating Cash Flow	$2.20B -23.3%	$2.88B +85.9%	$1.55B +11.8%	$1.38B -62.0%	$3.64B -13.9%	$4.23B

AI Insight: BIIB Financial Trends

Revenue remains range-bound near $2.5B while profitability deteriorated sharply in Q4 2025, swinging to a $49M loss.

• Net income declined from $584M in Q2 2024 to $320M in Q1 2026, with Q4 2025 posting a $49M loss.

• Revenue flat-to-declining; Q1 2026 at $2,478M versus $2,465M in Q2 2024, showing no meaningful growth.

• Operating cash flow volatile; Q3 2025 peaked at $1,272M but Q1 2026 fell to $646M, averaging weak.

⚠ Q4 2025 net loss signals potential operational strain; recovery unclear despite Q1 2026 return to $320M profit.

⚠ Total debt stable around $6.3B but profitability collapse raises leverage concerns if losses persist.

AI Insight: BIIB Ratio Trends

Biogen's profitability collapsed in Q4 2025 with negative margins across all metrics, followed by a partial recovery in Q1 2026 that remains well below historical levels.

• Operating margin plunged to -2.5% in Q4 2025 from 22.0% in Q3 2025, then rebounded to 15.2% in Q1 2026—still 13pp below Q2 2025's 28.1%.

• ROIC contracted sharply to -3.6% in Q4 2025 from 35.5% in Q3 2025, recovering to 24.0% in Q1 2026 but trailing the 44.4% peak in Q2 2024.

• TTM operating margin of 16.3% and ROIC of 25.8% reflect the Q4 2025 loss drag; early-2026 stabilization suggests the Q4 event may be resolving.

⚠ Q4 2025 negative profitability across all metrics (OpMargin -2.5%, NPM -2.1%, ROA -0.7%, ROIC -3.6%) indicates a significant charge or operational disruption.

⚠ Persistent margin volatility: Q2 and Q3 peaks (28%+ OpMargin) followed by Q4 cliff suggest lumpy earnings, potentially from product mix, charges, or pipeline disappointments.

Get alerted when BIIB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BIOGEN INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BIIB

BlackRock, Inc.
$2.9B15,974,601 sh
PRIMECAP MANAGEMENT CO/CA/
$2.7B14,757,607 sh
FMR LLC
$2.3B12,807,541 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.7B9,537,417 sh
STATE STREET CORP
$1.3B7,167,922 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.2B6,531,727 sh
GEODE CAPITAL MANAGEMENT, LLC
$793.4M4,342,602 sh
WELLINGTON MANAGEMENT GROUP LLP
$543.0M2,961,641 sh
MORGAN STANLEY
$398.0M2,170,940 sh
AQR CAPITAL MANAGEMENT LLC
$346.2M1,923,557 sh

Fund	Value	Shares
BlackRock, Inc.	$2.9B	15,974,601
PRIMECAP MANAGEMENT CO/CA/	$2.7B	14,757,607
FMR LLC	$2.3B	12,807,541
VANGUARD CAPITAL MANAGEMENT LLC	$1.7B	9,537,417
STATE STREET CORP	$1.3B	7,167,922
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.2B	6,531,727
GEODE CAPITAL MANAGEMENT, LLC	$793.4M	4,342,602
WELLINGTON MANAGEMENT GROUP LLP	$543.0M	2,961,641
MORGAN STANLEY	$398.0M	2,170,940
AQR CAPITAL MANAGEMENT LLC	$346.2M	1,923,557

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BIIB on your watchlist

Track score changes the day BIOGEN INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BIIB a good stock to buy?

13F Pro's AI-powered analysis of BIOGEN INC. (BIIB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BIIB are available on the BIIB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BIIB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BIIB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIOGEN INC.'s investment landscape.